Cambium Bio Successfully Closes A$3.0M Financing Round
December 04, 2024 22:58 ET
|
Cambium Bio Limited
Cambium Bio Successfully Closes A$3.0M Financing Round
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
October 30, 2024 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
OKYO Pharma Announces Chairman Acquires Shares
September 10, 2024 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Announces Chairman Acquires Shares
September 05, 2024 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
August 27, 2024 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 15, 2024 12:13 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
August 06, 2024 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
July 11, 2024 07:00 ET
|
OKYO Pharma LTD
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin...
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
July 10, 2024 07:00 ET
|
OKYO Pharma LTD
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease...
Allergic Conjunctivitis Market Research 2024-2032 with Focus on North America
June 25, 2024 10:03 ET
|
Research and Markets
Dublin, June 25, 2024 (GLOBE NEWSWIRE) -- The "Global Allergic Conjunctivitis Market Report by Disease Type, Drug class, Distribution Channel, Countries and Company Analysis, 2024-2032" report has...